Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN

Cinzia Nobile1, Arnaud Moris, Françoise Porrot

  • 1Virus and Immunity Group, URA CNRS 1930, Institut Pasteur, 75724 Paris Cedex 15, France.

Journal of Virology
|April 15, 2003
PubMed

Insights

DC-SIGN enhances human immunodeficiency virus (HIV) capture and internalization by immune cells. However, this lectin inhibits viral fusion and syncytium formation, impacting HIV-1 replication dynamics.

Area of Science:

  • Immunology
  • Virology
  • Cell Biology

Background:

  • Dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN) is a lectin found on immune cells.
  • DC-SIGN binds to human immunodeficiency virus (HIV) envelope glycoproteins, facilitating viral capture.
  • The precise role of DC-SIGN in HIV infection and cell-to-cell transmission remains unclear.

Purpose of the Study:

  • To investigate the effects of DC-SIGN on HIV entry and Env-induced syncytium formation.
  • To elucidate the cellular mechanisms by which DC-SIGN influences early HIV-1 replication steps.

Main Methods:

  • Analysis of viral entry and syncytium formation in DC-SIGN expressing cells.
  • Quantification of virion internalization and intracellular trafficking.
  • Assessment of the impact of CD4 surface levels and fusion inhibitors on DC-SIGN function.

Main Results:

  • DC-SIGN expression enhanced HIV susceptibility and virion internalization.
  • Captured virions accumulated in vesicular compartments with altered cytosolic access.
  • DC-SIGN inhibited syncytium formation, an effect partially reversed by increased CD4 levels.
  • The fusion inhibitor T-20 remained effective in DC-SIGN expressing cells.

Conclusions:

  • DC-SIGN plays a complex role in early HIV-1 replication, facilitating viral capture and internalization.
  • DC-SIGN inhibits viral fusion and syncytium formation, potentially through competition with CD4 for Env binding.
  • These findings offer insights into DC-SIGN's intricate modulation of HIV infection pathways.